Clinical Trial Update: A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1 [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study evaluating the safety, tolerability, and efficacy of SAR446268, an adeno-associated viral vector-mediated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myotonic Dystrophy Type

Drugs mentioned

• SAR446268

Snippet

Sponsor: Sanofi | Conditions: Myotonic Dystrophy | Phase 1, Phase 2 | Status: RECRUITING